In terms of OS, patients with advanced NSCLC who received PD-1 or PD-L1 inhibitors as second-line or later-line treatment had a significantly reduced risk of mortality than those who received conventional chemotherapy (HR 0.71, 95%CI 0.66–0.77, P < .001). The gene discussed is CD274; the disease is non-small cell lung carcinoma.